Vimarsana
Biggest News Aggregation in the World

Diversion Control News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diversion Control. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diversion Control Today - Breaking & Trending Today

SEE WHY: Tallahassee physician agrees to pay $60,000 - Vimarsana News

SEE WHY: Tallahassee physician agrees to pay $60,000

Dr. Mary C. Watson of Tallahassee, Florida, settled potential violations of the Controlled Substances Act.

Source: wtxl.com
The street drug alarming physicians that's 10x more potent than fentanyl - Vimarsana News

The street drug alarming physicians that's 10x more potent than fentanyl

Synthetic drugs called nitazenes, 10 times more potent than fentanyl, are becoming more commonly used in street drugs.

20 Most Used Illegal Drugs in the US - Insider Monkey - Vimarsana News

20 Most Used Illegal Drugs in the US - Insider Monkey

Drug abuse is one of the major problems globally. People who use recreational drugs are equal to the number of people in the United States, which is one of the most populous nations in the world.

DEA Extends Telemedicine Flexibilities for Prescribing of Controlled Medications: Second Time is the Charm | Foley & Lardner LLP - Vimarsana News

DEA Extends Telemedicine Flexibilities for Prescribing of Controlled Medications: Second Time is the Charm | Foley & Lardner LLP

On October 6, 2023, the Drug Enforcement Administration (DEA) released a second temporary rule extending the COVID-19 Telemedicine Flexibilities for Prescription of Controlled...

Revolving door redux: The DEA's recently departed No. 2 returns to a Big Pharma consulting firm - Vimarsana News

Revolving door redux: The DEA's recently departed No. 2 returns to a Big Pharma consulting firm

Washington’s revolving door kept spinning this week as the Drug Enforcement Administration’s recently departed second-in-command returned for another stint with a high-powered consulting firm where he previously advised OxyContin maker